Status:

COMPLETED

A Translational Approach to Gitelman Syndrome

Lead Sponsor:

Oregon Health and Science University

Collaborating Sponsors:

Oregon Clinical and Translational Research Institute

Conditions:

Gitelman Syndrome

Eligibility:

All Genders

21-65 years

Phase:

NA

Brief Summary

This study will test the response to a single dose of thiazide diuretic as a diagnostic test for Gitelman syndrome. Individuals with hypokalemic alkalosis will be enrolled. After a baseline study, the...

Detailed Description

The purpose of this study is to test the hypothesis that Gitelman syndrome (GS) can be diagnosed using a simple clinical protocol. GS is an inherited kidney disease that usually shows up in patients a...

Eligibility Criteria

Inclusion

  • Institutional Review Board (IRB) approved written Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization as per national regulations, must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
  • Subject is between the ages of 21 and 60.
  • Female subjects of child bearing potential must have a negative urine pregnancy test at the screening visit (Study Visit 1) and must agree to maintain effective birth control during the study.
  • Subjects who are referred to Dr. Ellison for evaluation of normotensive hypokalemia of unknown etiology

Exclusion

  • Subject has known allergy to thiazide or sulfonamide medications
  • Subject is pregnant or lactating.
  • Subject has major systemic illnesses that affect potassium regulation through pathology or pharmacologic treatment. This category includes:
  • Hypertension
  • Requiring regular pharmacological control
  • History of blood pressure greater than 140mmHg systolic and 90mmHg diastolic
  • Congestive heart failure
  • Cirrhosis of the liver
  • Subject has documented kidney disease resulting in anuria, proteinuria or abnormal urinalysis, or requiring dialysis for treatment.

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2013

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT00822107

Start Date

January 1 2009

End Date

September 1 2013

Last Update

April 5 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Oregon Health & Science University

Portland, Oregon, United States, 97239